Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma

Leo I. Gordon, Thomas Witzig, Arturo Molina, Myron Czuczman, Christos Emmanouilides, Robin Joyce, Katie Vo, Charles Theuer, Brad Pohlman, Nancy Bartlett, Greg Wiseman, Mohamed Darif, Christine White

Research output: Contribution to journalArticlepeer-review

112 Scopus citations

Fingerprint

Dive into the research topics of 'Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science